Video Series

While next-generation sequencing (NGS) has become routine in academic settings, its use for patients with follicular lymphoma in the community is less consistent.

Current NCCN Guidelines recommend molecular testing for patients with follicular lymphoma, which has improved diagnostic accuracy and can assist in selecting the appropriate treatment in certain cases.

Panelists discuss how structured, multidisciplinary screening efforts can catch MASH earlier and prevent progression.

Ryan Haumschild, PharmD, MS, MBA, introduces the faculty and sets the agenda to explore disease background, novel therapies, and operational considerations in relapsed/refractory multiple myeloma.

Ryan Haumschild, PharmD, MS, MBA, introduces the faculty and sets the agenda to explore disease background, novel therapies, and operational considerations in relapsed/refractory multiple myeloma.

Panelists discuss how metabolic dysfunction drives liver injury, highlighting early recognition of the obesity–MASH connection as key to prevention.

Panelists discuss their excitement about the evolution of heart failure as a distinct specialty with multiple effective therapeutic options, the convergence of previously siloed medical disciplines around shared evidence-based therapies that treat root causes of multiple comorbidities, and emerging technologies like clinical decision support systems and remote patient monitoring to improve population health management and prevent hospitalizations.

Panelists discuss how removing LDL-C targets in 2013 shifted focus from outcomes to statin use, weakening control efforts.

Panelists discuss how social determinants such as access, income, and literacy drive disparities in LDL-C control.

Panelists discuss how SC delivery enhances patient convenience and health care efficiency in NSCLC treatment.

Panelists discuss how community and academic settings differ in applying third-line therapies for metastatic colorectal cancer and how collaboration benefits patients.

Panelists discuss how future RWE should expand to include survival, quality of life, and safety data to improve third-line mCRC care.

Panelists discuss how negative symptoms like lack of motivation, social withdrawal, and impaired expression significantly impact patients’ ability to maintain relationships and employment, representing a challenging aspect of care with limited effective treatment options.

Panelists discuss how physician assistants play an essential role in addressing the critical shortage of psychiatrists, particularly in rural areas, where 55% of US counties lack a single psychiatric provider and 143 million Americans live in psychiatric shortage areas.

Panelists discuss how oral azacitidine plus venetoclax represents a transformative advance toward completely oral regimens that could dramatically improve quality of life and accessibility, though challenges remain regarding cost, insurance coverage, and the complexity of managing multiple oral agents.

Panelists discuss how emerging therapies like menin inhibitors show promise based on strong preclinical data and clinical responses, while CD47 inhibitors have faced setbacks in phase 3 trials, with the greatest potential for novel agents likely in frontline combination settings.

Panelists discuss how payers typically require step therapy with SGLT2 inhibitors before approving nonsteroidal MRAs due to cost considerations, while acknowledging the need for head-to-head trials to determine incremental benefits, though early clinical experience suggests good tolerability and the potential for combination therapy initiation rather than sequential treatment approaches.

Panelists discuss how nonsteroidal MRAs like finerenone differ mechanistically from steroidal MRAs by lacking steroid rings (reducing steroid-related adverse effects like gynecomastia), having different mineralocorticoid receptor binding patterns, shorter half-lives, and potentially lower hyperkalemia risk, with strong evidence supporting their use in heart failure with preserved ejection fraction and additive benefits when combined with SGLT2 inhibitors.

Panelists discuss how real-world programs like PROMPT-LIPID expose undertreatment patterns and guide care improvement.

Panelists discuss how pharmacy-related delays and limited escalation practices widen LDL-C management gaps.

Experts discuss the complexities of treatment sequencing in cancer therapy, emphasizing the importance of using the best therapies upfront for optimal outcomes.

Panelists discuss how proactive AE management optimizes safety and adherence with emerging EGFR-targeted regimens.

Panelists discuss how RWE informs treatment and safety decisions for special populations such as patients with ECOG PS 2 with metastatic colorectal cancer.

Panelists discuss how PROs, particularly tolerability and fatigue, guide shared decision-making for third-line therapy in mCRC.

Panelists discuss how venetoclax management requires standardized approaches to duration, bone marrow biopsy timing, growth factor use, and azole antifungal selection, with practices varying significantly between centers and the need for consistent protocols to optimize patient outcomes.

Panelists discuss how managed care organizations can leverage prescription digital therapeutics as cost-reduction tools to address quality metrics and offset financial impacts from health care policy changes while identifying education of providers about workflow impacts and value propositions as the biggest unmet need for wider adoption in mental health conditions.

Panelists discuss how insurance coverage for prescription digital therapeutics remains uneven due to uncertain reimbursement pathways, lack of awareness among health care leaders, challenges in demonstrating cost-effectiveness, provider workflow concerns, and technical barriers including coding issues and limited electronic health record integration.

Panelists discuss how IDH inhibitors, particularly ivosidenib combined with azacitidine, represent potentially the greatest advance in AML treatment due to significant overall survival improvements, though adoption challenges include waiting for mutation results and limited patient applicability.